Nupathe, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 14
- Market Cap
- -
- Website
- http://www.nupathe.com
Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
Phase 1
Completed
- Conditions
- Acute Migraine
- Interventions
- Drug: PROT-CL-NP101-015.01
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02684409
Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults
Phase 1
Completed
- Conditions
- Compare Bioequivalence Patches Previously Used in the NP101-007 Study
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01381796
- Locations
- 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 514
- Registration Number
- NCT00806546
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00792103
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: NP101 - Sumatriptan iontophoretic transdermal patchDrug: Placebo
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT00724815
Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: NP101 Study Patch
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00723983
- Locations
- 🇺🇸
MD Clinic, Hallandale Beach, Florida, United States
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00720018
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00546650
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath